Data sourced from ClinicalTrials.gov (NIH registry) Updated weekly IRB-supervised studies only
Home/MI/Muskegon
Updated November 2026 from ClinicalTrials.gov

Paid Clinical Trials in Muskegon, MI

Studies commonly pay $75 to $4,500 per completed study

65 clinical trials are currently recruiting participants within 30 miles of Muskegon. Listings below come straight from the official NIH registry, alongside the area's top-rated research centers with real Google reviews.

65studies recruiting
3+research centers nearby
3condition categories
Live from the NIH registry

Studies recruiting near Muskegon right now

Top 25 of 65 recruiting studies, sorted by proximity — each links to its official registry page

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma Phase 3 Interventional 880 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 Phase 3 Interventional 1,875 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma Phase 3 Interventional 288 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma Phase 2, Phase 3 Interventional 189 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 Phase 3 Interventional 1,524 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm N/A Observational 5,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute LAO

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma Phase 2 Interventional 372 participants sought
The Cancer & Hematology Centers — Norton Shores, Michigan (4.1 mi) · Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma Phase 3 Interventional 360 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma Phase 3 Interventional 510 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma Phase 2 Interventional 46 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Phase 3 Interventional 94 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Mesothelioma, Non Small Cell Lung Cancer Phase 1 Interventional 336 participants sought
Cancer and Hematology Centers of Western Michigan — Norton Shores, Michigan (4.1 mi) · Sponsor: Bristol-Myers Squibb

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lung Non-Small Cell Carcinoma Phase 2 Interventional 88 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 Phase 3 Interventional 486 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Phase 3 Interventional 247 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

Project: Every Child for Younger Patients With Cancer

Adrenal Gland Pheochromocytoma, Carcinoma In Situ N/A Observational 75,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Children's Oncology Group

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma Phase 2 Interventional 81 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Hodgkin Lymphoma, Non-Hodgkin Lymphoma N/A Observational 2,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma Phase 3 Interventional 264 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos N/A Interventional 535 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia Phase 3 Interventional 303 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia Phase 2 Interventional 461 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma Phase 3 Interventional 255 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian Carcinoma N/A Interventional 1,956 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Pancreatic Neoplasm N/A Observational 770 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
Actively enrolling

Studies you may be able to join near Muskegon

These studies are recruiting through partner research networks. We may be paid a referral fee if you complete their screening form — this never changes what you pay (nothing) or the compensation the study offers you.

See which clinical studies you may qualify for

A partner research network matches volunteers with studies that are currently enrolling in the United States. You answer a few screening questions about your health and where you live; if a study looks like a fit, its team contacts you to confirm eligibility.

Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.

Google-rated

Top-rated research centers in Muskegon

Dedicated clinical research sites near you — with their real Google ratings, reviews and contact details

West Michigan Clinical Research Center

2093 Health Dr SW Ste 201, Wyoming, MI 49519
(616) 328-5344

Center for Clinical Research at WMed

★ 5.0 (1 reviews)
1000 Oakland Dr, Kalamazoo, MI 49008
(269) 337-4264
"I would like overnight clinic study paid. Kalamazoo"
— Terri Dee Little, 5★

The Cancer & Hematology Centers

★ 4.8 (368 reviews)
6425 Harvey St, Norton Shores, MI 49444
(231) 737-3469
"When you get checked in for your appointment make sure that if you pay you get a receipt. There was only 1 month I did not pay because of a lost car…"
— Rebecca Provatas, 1★

Clinical trials in Muskegon: what's recruiting

The Muskegon area currently has 65 studies open to new participants, according to the ClinicalTrials.gov registry maintained by the U.S. National Institutes of Health. Among the studies closest to Muskegon, the most active research areas are:

  • Cancer & Oncology22 studies
  • Lungs & Breathing1 studies
  • Liver & Kidney1 studies

Every listing shows the study phase, the recruiting site and its distance from Muskegon, and links to the official registry page where eligibility criteria and study contacts are published. Compensation is set by each sponsor: industry surveys report typical payments of $75 to $4,500 per completed study, with short observational studies at the low end and multi-visit or overnight Phase 1 studies at the high end.

How to enroll in a paid study in Muskegon

Start with a study whose condition matches your profile — or a healthy-volunteer study if you have no diagnosis. Contact the research site through the registry page, complete a short phone screen, then attend an in-person screening visit. If you qualify, the study team walks you through the informed consent document, which details every procedure, risk and payment before you commit. You can withdraw at any point, and enrollment is always free.

Muskegon participants can also register with the dedicated research centers listed above — many maintain volunteer databases and call when a matching study opens — or sign up for our email alert below to hear when a new study starts recruiting within 30 miles of your ZIP code.

Frequently asked questions

How much do paid clinical trials in Muskegon pay?
Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.
Are clinical trials in Muskegon safe?
Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.
How do I join a study in Muskegon, MI?
Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.
Is compensation for clinical trials taxable?
In the U.S., clinical trial compensation is generally considered taxable income, and research sites may issue a 1099 form for payments above $600 in a year. Reimbursements for travel or meals are typically treated differently. Consult a tax professional for your situation.
Can I be in more than one clinical trial at a time?
Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Muskegon typically complete one or two studies per year.

Paid clinical trials near Muskegon

Other metros within reach

By condition

Eligibility and exclusions, condition by condition

More of MI

New paid studies open every week

Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.

Get free trial alerts